Beth Hoffman net worth
Quick answer
Beth Hoffman's estimated net worth is $20.0M (range $14.0M – $30.0M) as of 2026. Beth Hoffman is Founder at Origami Therapeutics, Inc.. Origami Therapeutics, Inc. valuation.
Beth Hoffman is Founder at Origami Therapeutics, Inc. (YC W22). Independent Entrepreneurial Check model estimate from public YC data.
At a glance
- Company status: Active
- Education: B.S. in Bioengineering from Stanford University
- Region: United States of America
- Industries: Healthcare, Therapeutics
- Team size: 4
- Website: http://origamitherapeutics.com
Who is Beth Hoffman?
Beth Hoffman is a founder at Origami Therapeutics, Inc., which is part of Y Combinator's Winter 2022 batch.
Highlights:
- Stanford University
- University of California, Berkeley
- Y Combinator W22
About Origami Therapeutics, Inc.
Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and...
FAQ: Beth Hoffman net worth and Origami Therapeutics, Inc. valuation
What is Beth Hoffman's net worth?
Beth Hoffman's estimated net worth is $20.0M (range $14.0M – $30.0M) as of 2026. Beth Hoffman is Founder at Origami Therapeutics, Inc.. Entrepreneurial Check publishes an independent model-based estimate from public company and role data. Not verified net worth, and Entrepreneurial Check is not affiliated with Y Combinator or the profiled companies.
What is Origami Therapeutics, Inc. valuation?
Origami Therapeutics, Inc.'s estimated valuation on Entrepreneurial Check is $20.0M. That valuation, or a disclosed round when one is public, is the source for the paper-wealth estimate. Independent model output — not a verified appraisal or official mark.
What is Beth Hoffman's role?
Beth Hoffman is Founder at Origami Therapeutics, Inc., a Y Combinator-backed startup (batch W22).